The Law Office of
Roger G. Worthington P.C.
Asbestos Lawyers for Life
- The Law Office of Roger G. Worthington is a California Asbestos Law Firm that handles asbestos-related mesothelioma cases.
- Empower Yourself
  Call us now at 1-800-831-9399 to speak directly to one of our asbestos attorneys. Or...
  
  Click Here to receive a free packet of medical & legal information including medical experts, clinical trials, patient profiles and asbestos products.
- Mesothelioma Empowerment
  - Must Read Articles
- Asbestos Attorneys
- Asbestos Cancer
- Malignant Mesothelioma
- Mesothelioma Lawsuits
- Asbestos Legislation
- Mesothelioma Advocates

LATEST PROTOCOLS FOR NSCLClast updated April 27, 2005

ALIMTA

PDX

CELECOXIB

GVAC

TARCEV

IRESSA

VEGLIN

Therapeutic Progress in Metastatic NSCLC by David S. Ettinger, MD. Non-Small Cell Lung Cancer, treatments, survival benefits/risks and options in therapy (including Gefitnib and Erlotinib). (4/27/05)

Combating Chemotherapy Side Effects (3/29/05)

ALIMTA

FDA Endorses Eli Lilly Cancer Drug Alimta (pemetrexed) For Accelerated Approval in the Second-line Treatment of Non-small Cell Lung Cancer (7/28/04)
Alimta(R) Showed Advances over Taxotere(R) in Second-Line Non-Small Cell Lung Cancer Study (5/3/04)

CELECOXIB

Celecoxib May Increase Benefit of Erlotinib for Lung Cancer (6/14/06)

GVAC

Cell Genesys Initiates New Trial of Lung Cancer Drug - GVAC (6/30/04)
A Phase 2 Randomized Study of GM-CSF Gene-Modified Autologous Tumor Vaccine (CG8123) ("GVAX® Lung Cancer Vaccine") with and without Low-Dose Cyclophosphamide in Advanced Stage Non Small-Cell Lung Cancer (6/30/05)
GVAC Lung Cancer Vaccine (6/30/04)

IRESSA

New IRESSA(R) (Gefitinib) Data Presented in Bronchioalveolar Lung Cancer (6/5/04)
Retrospective Analysis of Response to Gefitinib ('Iressa', ZD1839) in Pre-treated Patients with Non-small-cell Lung Cancer (NSCLC): Influence of Histologic Subtype and Smoking History (6/1/04)
Discovery Promises Better Use of Iressa for Lung Cancer (4/29/04)
Iressa: In Japan,
Discovery Promises Better Use of Iressa for Lung Cancer (4/29/04)
FDA Approves Last Chance Drug for Lung Cancer (5/6/03)
Confidence High In Experimental Antitumor Agent Tarceva Despite Iressa Failure (10/11/02)
AstraZeneca Drug Trial Fails, Shares Down (Iressa) (8/21/02)
New Pill (Iressa) May Improve Lung Cancer (5/20/02)
ZD 1839 - Iressa (4/17/02)

PDX

Phase 1 PDX Study in Patients With Non-Small Cell Lung Cancer (1/20/05)

TARCEVA

Tarceva®, Formerly Known as OSI-774, An Epidermal Growth Factor Receptor (EGFR) Inhibitor (7/29/02)

VEGLIN

Research Shows Anti-Cancer Drug is Safe (Veglin) (7/15/04)
Veglin Phase I Trial Shows Potential in Fighting Angiogenesis and Tumor Progression (6/7/04)

* * * * * * * * * * *
Neither the Law Offices of Roger G. Worthington nor its clients herein (including clients of other law firms) intend to waive the attorney-client privilege by posting information about these clients herein. The information contained herein is intended to educate and inform asbestos cancer patients and their families of potential medical and legal options. Roger Worthington is not a medical doctor. Patients are advised to consult with a medical doctor and/or an attorney if they have questions regarding this information. The opinions expressed herein by persons other than Roger Worthington are not necessarily endorsed by the Law Offices of Roger G. Worthington, P.C. This is an open forum.

* * * * * * * * * * *

Empower Yourself

LATEST PROTOCOLS FOR NSCLClast updated April 27, 2005